Wild Family Office

Active

Updated: Apr 2, 2026 ·

Financial History

Total Raised

N/A

Valuation

N/A

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Jul 31, 2019	Sermonix Pharmaceuticals	$26.0M Series A	Thomas Pfisterer	Anthony Wild, Lodewijk de Vink, Richard DeSchutter
Oct 23, 2017	ADC Therapeutics	$200.0M Other Equity	AstraZeneca, Auven Therapeutics, Redmile Group, Wild Family Office	—
Oct 27, 2016	ADC Therapeutics	$105.0M Other Equity	—	AstraZeneca, Peter Corr

Total Raised

N/A

Valuation

N/A